Alzheimer's disease (AD) is a neurodegenerative disorder that leads to profound cognitive decline and eventually death. There are no effective treatments or preventative measures available, and the incidence and prevalence of the disease are increasing. New insights and tractable therapeutic targets are sorely needed. Genetic evidence indicates that a major cause of AD is the production of the ?-amyloid (A?) peptide. The A? peptide can oligomerize and be deposited as extracellular plaques in the brain and blood vessels, but the mechanism of how it leads to neuronal death is not known. There is increasing evidence of a vascular contribution in AD: patients suffer from brain hypoperfusion, the cerebral vasculature is damaged, and abnormal hemostasis is present. Circulatory deficiencies could therefore play an important role in the pathogenesis of this disease. We have demonstrated an increase in blood brain barrier (BBB) permeability and neurovascular damage in AD mice, and we showed that fibrin(ogen) deposition potentiates these processes. We have also found that A binds to fibrinogen and has a dramatic effect on fibrin clot formation. Clots formed in the presence of A? have an abnormal structure and are resistant to degradation by fibrinolytic enzymes. Therefore, in the presence of A?, any fibrin deposits formed would be more persistent and would exacerbate BBB damage, neuroinflammation, and neuronal death. In keeping with the known genetic interaction between AD and the ApoE genotype, we have also demonstrated that ApoE affects the interaction between fibrinogen and A? and the isoforms differentially influence fibrinogen deposition in the human brain. To further study the role of A? in fibrin clot formation, we will combine in vitro and in vivo techniques to analyze and characterize the interaction between A? and fibrinogen. The role of the various ApoE isoforms in this process will also be examined. Finally, we will examine the effects of fibrinogen deposition on the brain in the absence of A? to deduce the specific contribution of fibrin(ogen) to AD-related pathologies. The proposed experiments will define the role of fibrin(ogen) in AD and could lead to new therapeutic strategies for preventing or retarding progression of the disease.

Public Health Relevance

Alzheimer's disease (AD) affects a large and growing portion of the population and has been studied for over a century, yet there are few available therapies to aid in the loss of cognition and no effective preventative measures. We have found that the buildup of fibrin in the brains of AD mouse models is deleterious and contributes to their cognitive decline. The proposed studies will provide a new way to understand how this disease progresses from the perspective of disrupted blood flow to the brain, which will also explain how the nature of the fibrin clot is altered in the presence of ?-amyloid to allow for this persistence and how other genes can influence progression.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Corriveau, Roderick A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rockefeller University
Other Domestic Higher Education
New York
United States
Zip Code
Yao, Yao; Norris, Erin H; Strickland, Sidney (2015) The cellular origin of laminin determines its role in blood pressure regulation. Cell Mol Life Sci 72:999-1008
Cortes-Canteli, Marta; Mattei, Larissa; Richards, Allison T et al. (2015) Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol Aging 36:608-17
Hultman, K; Cortes-Canteli, M; Bounoutas, A et al. (2014) Plasmin deficiency leads to fibrin accumulation and a compromised inflammatory response in the mouse brain. J Thromb Haemost 12:701-12
Yao, Yao; Chen, Zu-Lin; Norris, Erin H et al. (2014) Astrocytic laminin regulates pericyte differentiation and maintains blood brain barrier integrity. Nat Commun 5:3413
Ahn, Hyung Jin; Glickman, J Fraser; Poon, Ka Lai et al. (2014) A novel A?-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med 211:1049-62
Chen, Zu-Lin; Yao, Yao; Norris, Erin H et al. (2013) Ablation of astrocytic laminin impairs vascular smooth muscle cell function and leads to hemorrhagic stroke. J Cell Biol 202:381-95
Hultman, Karin; Strickland, Sidney; Norris, Erin H (2013) The APOE ýý4/ýý4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J Cereb Blood Flow Metab 33:1251-8
Zamolodchikov, Daria; Strickland, Sidney (2012) A? delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood 119:3342-51
Cortes-Canteli, Marta; Paul, Justin; Norris, Erin H et al. (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 66:695-709
Cortes-Canteli, M; Strickland, S (2009) Fibrinogen, a possible key player in Alzheimer's disease. J Thromb Haemost 7 Suppl 1:146-50

Showing the most recent 10 out of 14 publications